Snowball logo
logo
PFER_logo

Pfizer Inc

₽980.00+₽16.00  (1.66%)
Estimate
P/E
0.3
EPS
107.613
Beta
0.272
Growth
Revenue, YoY
3.26%
Net income, YoY
-108.51%
FCF, YoY
125.33%
Forecast
P/E (FWD)
10.4
EPS (FWD)
2.897
Dividends
Dividend yield
14.12%
Annual payout
$1.72
Next ex. div date
November 6, 26
Payout
125.75%
Div.growth, 5y
3.59%
Dividend growth streak
15 y
Div.rating
About the company
Ticker
PFE-RM
ISIN
US7170811035
Country
United States of America
Sector (GICS)
Healthcare
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Frequently asked questions

What sector does Pfizer Inc (PFE-RM) operate in?

Pfizer Inc belongs to the Healthcare sector and operates in the Drug Manufacturers - General industry.

What is Pfizer Inc (PFE-RM) current stock price?

As of the latest data, Pfizer Inc stock price is RUB 980.00, with a previous close of RUB 964.00. Pfizer Inc gained RUB 16.00 in the last trading session, representing a 1.66% increase.

What is Pfizer Inc (PFE-RM) current market capitalization?

Pfizer Inc market cap is approximately 172.42 billion.

What is Pfizer Inc (PFE-RM) Earnings Per Share (EPS)?

The trailing EPS is RUB 107.61, and the forward EPS is RUB 2.90.

What is Pfizer Inc (PFE-RM) Price-to-Earnings (P/E) ratio?

Pfizer Inc current P/E ratio is 0.28, with a forward P/E of 10.44.

What is Pfizer Inc (PFE-RM) EBITDA?

Pfizer Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 94.36 billion.

Does Pfizer Inc (PFE-RM) pay dividends?

Yes. Pfizer Inc pays quarterly dividends with an annualized yield of 14.12% and an estimated annual payout of RUB 1.72 per share.

When is the next ex-dividend date for Pfizer Inc (PFE-RM)?

The next ex-dividend date is scheduled for November 06, 2026.

How did Pfizer Inc (PFE-RM) perform in its most recent earnings report?

In the last report (June 30, 2026), Pfizer Inc posted an EPS surprise of 13.24% and a revenue surprise of 8,123.25%.

When is Pfizer Inc (PFE-RM) next earnings report?

Pfizer Inc is expected to release its next earnings report on September 30, 2026.

What is Pfizer Inc (PFE-RM) beta (volatility) score?

Pfizer Inc has a beta of 0.272, indicating lower volatility than the overall market.